Merck buys controlling stake in Physicians Interactive

Share this article:

Merck's Global Health Innovation Fund (GHIF) has taken a controlling interest in digital physician marketing firm Physicians Interactive, MM&M has learned. Financial terms of the deal were not disclosed.

The takeover of Marlborough, MA-based Physician's Interactive, which provides online and mobile clinical tools and marketing to doctors like e-sampling and interactive education programs, follows a $17-million stake taken by GHIF in January 2012.

By expanding its stake in PI, Merck is deepening its relationship with a well-established provider of non-personal promotion to HCPs, a commodity in this era when drug makers are fielding much slimmer sales forces.

“PI offers low-cost, multi-channel, integrated marketing solutions and applications, generated from its online platform of user-generated, proprietary and public data, to enable medical professionals to deliver better patient care,” said Merck in a statement. “These programs can be used to supplement currently promoted products as well as non-promoted and orphaned products that still have value to physicians and patients.”

“PI will operate independently and maintain its own governance, policies and corporate IT infrastructure to ensure the security of its customers' data and intellectual property,” Merck added.

The previous majority owner of PI was private equity firm Perseus Capital.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...